MX2021002985A - Polipeptidos del factor vii de accion corta. - Google Patents

Polipeptidos del factor vii de accion corta.

Info

Publication number
MX2021002985A
MX2021002985A MX2021002985A MX2021002985A MX2021002985A MX 2021002985 A MX2021002985 A MX 2021002985A MX 2021002985 A MX2021002985 A MX 2021002985A MX 2021002985 A MX2021002985 A MX 2021002985A MX 2021002985 A MX2021002985 A MX 2021002985A
Authority
MX
Mexico
Prior art keywords
variants
factor vii
short
acting factor
vii polypeptides
Prior art date
Application number
MX2021002985A
Other languages
English (en)
Inventor
Terry Hermiston
Maxine Bauzon
Original Assignee
Coagulant Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51022016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021002985(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coagulant Therapeutics Corp filed Critical Coagulant Therapeutics Corp
Publication of MX2021002985A publication Critical patent/MX2021002985A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se divulgan péptidos del Factor VII de acción corta. Una vida media acortada es deseable para el tratamiento de hemorragia aguda y trastornos similares. La 5 modificación de la sialización y/o de la glucosilación del Factor VII y de variantes del mismo produjo péptidos útiles en el tratamiento de afecciones de hemorragia aguda.
MX2021002985A 2012-12-24 2015-06-16 Polipeptidos del factor vii de accion corta. MX2021002985A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745674P 2012-12-24 2012-12-24
US201361787026P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
MX2021002985A true MX2021002985A (es) 2021-05-14

Family

ID=51022016

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007712A MX2015007712A (es) 2012-12-24 2013-12-23 Polipeptidos del factor vii de accion corta.
MX2021002985A MX2021002985A (es) 2012-12-24 2015-06-16 Polipeptidos del factor vii de accion corta.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015007712A MX2015007712A (es) 2012-12-24 2013-12-23 Polipeptidos del factor vii de accion corta.

Country Status (21)

Country Link
US (5) US20150344863A1 (es)
EP (3) EP3572090B1 (es)
JP (3) JP6566869B2 (es)
KR (2) KR102047235B1 (es)
CN (2) CN105025913A (es)
AU (2) AU2013370522B2 (es)
BR (1) BR112015015182B1 (es)
CA (2) CA3185756A1 (es)
DK (3) DK3572090T3 (es)
ES (3) ES2747726T3 (es)
HK (1) HK1216855A1 (es)
IL (2) IL239345B (es)
MX (2) MX2015007712A (es)
NZ (1) NZ708873A (es)
PE (2) PE20211303A1 (es)
PL (3) PL2938351T3 (es)
SA (1) SA517380867B1 (es)
SG (2) SG10201710593UA (es)
TW (3) TWI743542B (es)
WO (1) WO2014105784A1 (es)
ZA (1) ZA201505315B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3572090T3 (da) 2012-12-24 2023-01-09 Coagulant Therapeutics Corp Korttidsvirkende faktor-vii-polypeptider
TW201629215A (zh) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 使用凝血酶之組成物及治療方法
KR101755838B1 (ko) 2015-09-09 2017-07-07 현대자동차주식회사 엔진 예열장치 및 그 예열방법
CA3036527A1 (en) * 2016-09-13 2018-03-22 Bayer Healthcare Llc Factor viia glycoforms
KR102120921B1 (ko) * 2017-02-10 2020-06-10 주식회사 일리아스바이오로직스 Gba 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 고셔병 예방 및 치료용 약학적 조성물
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008252A (en) 1959-02-02 1961-11-14 Beatrice V Robinson Puffed sleeve ironer
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
FR2632524B1 (fr) * 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
ATE280590T1 (de) 2000-05-23 2004-11-15 Neurologix Inc Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US20050221335A1 (en) 2001-12-14 2005-10-06 Anthony Kavanagh Reporter gene
NZ536340A (en) * 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
AU2004221761B2 (en) * 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
PT1644504E (pt) * 2003-06-19 2010-03-22 Bayer Healthcare Llc Variantes do domínio gla dos factores vii ou viia
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
CN101870729A (zh) * 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
WO2005080585A1 (en) 2004-02-13 2005-09-01 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
WO2005108568A1 (en) 2004-05-10 2005-11-17 Basf Plant Science Gmbh Methods for assembling multiple expression constructs
WO2005123916A2 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care Ag Glycosylation-disrupted factor vii variants
AU2006222187A1 (en) 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
EP1893230A2 (en) * 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
US20070129298A1 (en) * 2005-07-22 2007-06-07 Maxygen Holdings, Ltd. In-solution activation of factor vii
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
KR20080080081A (ko) * 2005-08-19 2008-09-02 네오스 테크놀로지스, 인크. 글리코페닐화 인자 ⅶ 및 인자 ⅶ에이
AU2006313491B2 (en) * 2005-11-08 2011-01-06 Astellas Pharma Inc. Compositions and methods for treating thrombocytopenia
WO2007131179A1 (en) * 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
US7532621B2 (en) 2006-08-30 2009-05-12 Cornell Research Foundation, Inc. Lateral error correction for time-critical multicast
KR101427434B1 (ko) 2006-12-20 2014-09-19 스미또모 가가꾸 가부시키가이샤 편광판 및 액정 표시 장치
CN105056231A (zh) 2006-12-28 2015-11-18 詹森生物科技公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
ES2492469T3 (es) * 2007-02-20 2014-09-09 Dsm Ip Assets B.V. Nueva sialidasa
CA2683423C (en) 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
AU2008310583A1 (en) 2007-10-12 2009-04-16 Sigma-Aldrich Co. Llc Compositions and methods for improved glycoprotein sialylation
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
US8557773B2 (en) * 2008-05-02 2013-10-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Treatment of bleeding with low half-life fibrinogen
JP2010022253A (ja) * 2008-07-17 2010-02-04 Kaneka Corp アシアロ糖鎖化合物の作製方法
EP2381920A4 (en) 2008-12-05 2013-04-17 Univ California METHOD AND COMPOSITIONS FOR TREATING P.ACNES
US8400974B2 (en) * 2009-07-30 2013-03-19 Apple Inc. Methods and apparatus for providing dynamic information in a wireless information channel
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
WO2013017555A1 (en) * 2011-08-01 2013-02-07 Lfb-Biotechnologies Factor vii compositions with specific glycosylation for controlled half-life
DK3572090T3 (da) 2012-12-24 2023-01-09 Coagulant Therapeutics Corp Korttidsvirkende faktor-vii-polypeptider

Also Published As

Publication number Publication date
BR112015015182B1 (pt) 2023-12-26
AU2019202663B2 (en) 2020-09-10
PL3572090T3 (pl) 2023-04-11
IL239345A0 (en) 2015-07-30
ES2747726T3 (es) 2020-03-11
SA517380867B1 (ar) 2020-06-10
PE20151206A1 (es) 2015-09-04
TWI708783B (zh) 2020-11-01
JP2017071608A (ja) 2017-04-13
CN105025913A (zh) 2015-11-04
AU2013370522A2 (en) 2016-10-06
NZ708873A (en) 2019-11-29
US10717970B2 (en) 2020-07-21
IL273559B (en) 2022-04-01
AU2013370522A1 (en) 2015-07-09
TW201431876A (zh) 2014-08-16
BR112015015182A2 (pt) 2019-07-30
CA2896057A1 (en) 2014-07-03
ES2936485T3 (es) 2023-03-17
EP2938351A1 (en) 2015-11-04
JP6566869B2 (ja) 2019-08-28
JP2016507506A (ja) 2016-03-10
EP3572090B1 (en) 2022-12-14
US20160376578A1 (en) 2016-12-29
EP3165232B1 (en) 2019-07-10
AU2019202663A1 (en) 2019-05-09
PL3165232T3 (pl) 2019-12-31
JP6363677B2 (ja) 2018-07-25
KR20190072686A (ko) 2019-06-25
US20230295596A1 (en) 2023-09-21
DK3572090T3 (da) 2023-01-09
PE20211303A1 (es) 2021-07-20
KR102047235B1 (ko) 2019-11-22
MX2015007712A (es) 2015-09-07
EP2938351B8 (en) 2019-07-31
EP2938351A4 (en) 2016-08-24
CA3185756A1 (en) 2014-07-03
TW202026309A (zh) 2020-07-16
TWI681968B (zh) 2020-01-11
ZA201505315B (en) 2022-11-30
KR102111934B1 (ko) 2020-05-18
EP2938351B1 (en) 2019-06-26
TWI743542B (zh) 2021-10-21
DK2938351T3 (da) 2019-09-23
PL2938351T3 (pl) 2020-03-31
EP3165232A1 (en) 2017-05-10
DK3165232T3 (da) 2019-09-16
IL239345B (en) 2020-04-30
NZ749488A (en) 2021-09-24
US10273466B2 (en) 2019-04-30
CN107099522A (zh) 2017-08-29
JP2019213540A (ja) 2019-12-19
US20210002624A1 (en) 2021-01-07
KR20150127573A (ko) 2015-11-17
ES2746116T3 (es) 2020-03-04
US20150344863A1 (en) 2015-12-03
US20140363419A1 (en) 2014-12-11
HK1216855A1 (zh) 2016-12-09
CA2896057C (en) 2023-03-14
SG10201710593UA (en) 2018-02-27
EP3572090A1 (en) 2019-11-27
WO2014105784A1 (en) 2014-07-03
SG11201504986QA (en) 2015-07-30
TW201920254A (zh) 2019-06-01
US11530401B2 (en) 2022-12-20
AU2013370522B2 (en) 2019-01-17
IL273559A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
MX2021002985A (es) Polipeptidos del factor vii de accion corta.
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
IL294314A (en) Proteins based on the scaffolding domain of fibronectin that bind to myostatin
MX2016003943A (es) Composiciones y formulaciones para la prevencion y reduccion de tumorigenesis, invasion y proliferacion de celulas de cancer y metodos de produccion y uso en el tratamiento del cancer.
AU2017261625B2 (en) Non-natural consensus albumin binding domains
MY167232A (en) Polypeptides binding to human complement c5
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
WO2013151736A3 (en) In vivo production of proteins
MY176820A (en) Egfr and c-met fibronectin type iii domain binding molecules
EA201591367A1 (ru) Соединения резорцина для дерматологического применения
EP4223772A3 (en) Optimized factor viii gene
MD4548C1 (ro) Polipeptide care se leagă de CX3CR1
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
WO2014140103A3 (en) Thrombin sensitive coagulation factor x molecules
WO2015081306A3 (en) Peptide tyrosinase activators
WO2010086838A3 (en) Non-ad5 adenoviral vectors and methods and uses related thereto
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2013001836A (es) Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc.
WO2013109190A3 (en) Cho-gmt recombinant protein expression
WO2015054439A3 (en) Hybrid factor viii polypeptides for use to treat hemophilia a
PH12016501132A1 (en) A process for preparing a composition of pegylated proteins
WO2014115087A3 (en) A method for the preparation of recombinant human prothrombin and fibrinogen
GB0818080D0 (en) Immunogenic peptides